Back to results
US 2006/0079456 A1Published application
Vasoactive intestinal polypeptide pharmaceuticals
AssigneeTherapei Pharmaceuticals, Inc.
InventorJohn Nestor
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed.
Claims19
A vasoactive intestinal polypeptide selected from the group consisting of:
- (a) a polypeptide corresponding to Formula (I):
- FORMULA (I)
- Acyl-His-Ser-Asp-aa1-aa2-Phe-Thr-aa3-aa4-Tyr-aa5-
- Arg-aa6-Arg-Lys-Gln-aa7-Ala-aa8-Lys-Lys-Tyr-Leu-
- aa9-aa10-aa11-aa12-aa13-aa14-aa15-aa16-Haa-(Laa-
- Laa-Haa-Haa)n-Laa-
- Lys(ε-long acyl)-X
- wherein:
- n=1-3;
- Haa is a hydrophilic amino acid;
- Laa is a lipophilic amino acid;
- acyl is a C2-16 acyl chain;
- long acyl is a C12-24 acyl chain;
- X is OH or NHR1 where R1 is H or lower alkyl, haloalkyl, or PEG;
- aa1 is Gly or Ala;
- aa2 is Val, Ile, or Leu;
- aa3 is Asp or Arg;
- aa4 is Ser or Asn;
- aa5 is Ser or Thr;
- aa6 is Leu or Tyr;
- aa7 is Met, Leu, or Val;
- aa8 is Ala or Val;
- aa9 is Asn, Gln, or Ala;
- aa10 is Trp, Ala, or Ser;
- aa11 Ile or Val;
- aa12 is Leu or Lys;
- aa13 is Lys, Arg, Asn, or Gly;
- aa14 is Ala or Gly;
- aa15 is Lys or Arg;
- and
- aa16 is Lys or Arg;
- (b) a polypeptide corresponding to Formula (II):
- FORMULA (II)
- Acyl-His-Ser-Asp-aa1-aa2-Phe-Thr-aa3-aa4-Tyr-aa5-
- Arg-aa6-Arg-Lys-Gln-aa7-Ala-aa8-Lys-Lys-Tyr-Leu-
- aa9-aa10-aa11-aa12-aa13-aa14-aa15-aa16-Haa-(Laa-
- Laa-Haa-Haa)n-Laa-
- aa17-Pro-Pro-Pro-Lys(ε-
- long acyl)-X
- wherein:
- n=1-3;
- Haa is a hydrophilic amino acid;
- Laa is a lipophilic amino acid;
- acyl is a C2-16 acyl chain;
- long acyl is a C12-24 acyl chain;
- X is OH or NHR1 where R1 is H or lower alkyl, haloalkyl, or PEG;
- aa1 is Gly or Ala;
- aa2 is Val, Ile, or Leu;
- aa3 is Asp or Arg;
- aa4 is Ser or Asn;
- aa5 is Ser or Thr;
- aa6 is Leu or Tyr;
- aa7 is Met, Leu, or Val;
- aa8 is Ala or Val;
- aa9 is Asn, Gln, or Ala;
- aa10 is Trp, Ala, or Ser;
- aa11 is Ile or Val;
- aa12 is Leu or Lys;
- aa13 is Lys, Arg, Asn, or Gly;
- aa14 is Ala or Gly;
- aa15 is Lys or Arg;
- aa16 is Lys or Arg;
- and
- aa17 is absent or Gln;
- (c) a polypeptide corresponding to Formula (III):
- FORMULA (III)
- Acyl-His-Ser-Asp-aa1-aa2-Phe-Thr-aa3-aa4-Tyr-aa5-
- Arg-aa6-Arg-Lys-Gln-aa7-Ala-aa8-Lys-Lys-Tyr-Leu-
- aa9-aa10-aa11-aa12-aa13-aa14-aa15-aa16-Haa-(Laa-
- Laa-Haa-Haa)n-Laa-
- Lys(ε-long acyl)-PEG
- wherein:
- n=1-3;
- Haa is a hydrophilic amino acid;
- Laa is a lipophilic amino acid;
- acyl is a C2-16 acyl chain;
- long acyl is a C12-24 acyl chain;
- aa1 is Gly or Ala;
- aa2 is Val, Ile, or Leu;
- aa3 is Asp or Arg;
- aa4 is Ser or Asn;
- aa5 is Ser or Thr;
- aa6 is Leu or Tyr;
- aa7 is Met, Leu, or Val;
- aa8 is Ala or Val;
- aa9 is Asn, Gln, or Ala;
- aa10 is Trp, Ala, or Ser;
- aa11 is Ile or Val;
- aa12 is Leu or Lys;
- aa13 is Lys, Arg, Asn, or Gly;
- aa14 is Ala or Gly;
- aa15 is Lys or Arg;
- and
- aa16 is Lys or Arg;
- and
- (d) a polypeptide selected from SEQ ID NO:
- 1-SEQ ID NO:
- 38.
95 more elements
Dependencies are inferred from the claim text.